Match!
Christine Mateus
Institut Gustave Roussy
193Publications
33H-index
11.8kCitations
Publications 193
Newest
#1F. Herms (Paris Diderot University)H-Index: 1
#2Jérôme Lambert (Paris Diderot University)H-Index: 10
Last.Nicole Basset-Seguin (Paris Diderot University)H-Index: 36
view all 19 authors...
PURPOSEVismodegib is a hedgehog pathway inhibitor indicated for the treatment of locally advanced basal cell carcinoma (laBCC), with an objective response rate of 65%, including a 32% complete resp...
Source
#1S S Hajem (Paris V: Paris Descartes University)
#2C Baldini (Institut Gustave Roussy)H-Index: 2
Last.J-M Michot (Institut Gustave Roussy)H-Index: 5
view all 16 authors...
Source
#1Céline BoutrosH-Index: 5
#2Nathalie ChaputH-Index: 43
Last.Eric Deutsch (French Institute of Health and Medical Research)H-Index: 43
view all 20 authors...
Source
#1J-M Michot (Institut Gustave Roussy)H-Index: 5
#2A Lappara (Institut Gustave Roussy)
Last.O LambotteH-Index: 5
view all 20 authors...
Source
#1Jean-Marie MichotH-Index: 18
#2Mathilde Fusellier (Institut Gustave Roussy)H-Index: 1
Last.Olivier LambotteH-Index: 48
view all 15 authors...
We read with interest the study of Kostine et al describing rheumatic immune-related adverse events (irAE), which occur in 6.6% of patients treated for cancer by anti-programmed death-(ligand) 1 (PDL1).1 These new adverse effects pose significant challenges to patient care in terms of optimal management of these autoimmune damaging toxicities, while allowing effective antitumor therapy to continue. The PD(L)1 pathway is involved in the maintenance of immune tolerance, and the blockage of this ax...
5 CitationsSource
#1Karen Bitton (University of Paris-Sud)H-Index: 1
#2Jean-Marie Michot (Université Paris-Saclay)H-Index: 18
Last.Antoine RousseauH-Index: 20
view all 13 authors...
Purpose Immune checkpoint inhibitors (ICI) targeting the programmed cell death protein 1 (PD-1), or its ligand PD-L1, are the mainstay of metastatic cancer treatment. Patients receiving these treatments may develop immune-related adverse events (irAEs). This study aimed to estimate the prevalence and describe the clinical patterns of moderate-to-severe ocular irAEs-associated with anti-PD-(L)1 treatment. Design Prospective case series. Methods This study included patients recruited via (1) a sin...
3 CitationsSource
#1Tarek Assi (Université Paris-Saclay)
#2Alina Danu (Université Paris-Saclay)H-Index: 6
Last.Vincent Ribrag (Université Paris-Saclay)H-Index: 46
view all 12 authors...
Source
Source
#1Hassan Izzedine (University of Paris)H-Index: 16
#2Alexis MathianH-Index: 31
Last.Isabelle BrocheriouH-Index: 23
view all 19 authors...
7 CitationsSource
#1Alice de MaletH-Index: 1
#2Guillemette Antoni (French Institute of Health and Medical Research)H-Index: 5
Last.Franck CarbonnelH-Index: 41
view all 11 authors...
Abstract Background Immune checkpoint inhibitors (ICIs), such as anti–CTLA-4 and anti–PD-1 antibodies, are effective against several malignancies. They are associated with gastrointestinal immune-related adverse events (GI-IrAEs), which may be severe and lead to ICI discontinuation. We assessed the risk of evolution of GI-IrAEs to chronic GI inflammation and the risk of recurrence after a second line of ICI. Patients and methods This was a single-centre study. Included patients had a GI-IrAE due...
2 CitationsSource
12345678910